{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T16:39:58Z","timestamp":1768408798797,"version":"3.49.0"},"reference-count":15,"publisher":"American Society for Microbiology","issue":"11","license":[{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2013,11]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Drug resistance has become a global threat that, if not addressed, may return us to the preantibiotic era. A way to overcome the problem of growing incidence of global antibiotic resistance is to introduce compounds belonging to classes that are new to the clinic. During a screening of the marine microbial extract library for new antibiotics, one of the extracts showed promising antibacterial activity against Gram-positive organisms. Bioactivity-guided isolation and characterization of active metabolites led to the discovery of a novel thiazolyl cyclic-peptide antibiotic, PM181104. It was isolated and characterized from a marine sponge-associated actinobacterium strain of the genus\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Kocuria<\/jats:named-content>\n            (MTCC 5269). The compound exhibited a potent\n            <jats:italic>in vitro<\/jats:italic>\n            antibacterial activity against a broad range of Gram-positive bacteria, including methicillin-resistant\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Staphylococcus aureus<\/jats:named-content>\n            (MRSA) and vancomycin-resistant enterococci (VRE). The MIC values evaluated for the compound were found to be in the single-digit nanomolar range. In\n            <jats:italic>in vivo<\/jats:italic>\n            studies of PM181104 in a BALB\/c murine septicemia model, the compound displayed 100% effective dose (ED\n            <jats:sub>100<\/jats:sub>\n            ) values of 2.5 and 5.0 mg\/kg of body weight against MRSA and 10.0 mg\/kg against VRE. In this report,\n            <jats:italic>in vitro<\/jats:italic>\n            and\n            <jats:italic>in vivo<\/jats:italic>\n            studies of PM181104 are described.\n          <\/jats:p>","DOI":"10.1128\/aac.01059-13","type":"journal-article","created":{"date-parts":[[2013,8,13]],"date-time":"2013-08-13T03:35:50Z","timestamp":1376364950000},"page":"5315-5319","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":27,"title":["<i>In Vitro<\/i>\n            and\n            <i>In Vivo<\/i>\n            Activities of Antibiotic PM181104"],"prefix":"10.1128","volume":"57","author":[{"given":"Girish","family":"Mahajan","sequence":"first","affiliation":[{"name":"Piramal Enterprises Limited, Goregaon, Mumbai, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Becky","family":"Thomas","sequence":"additional","affiliation":[{"name":"Piramal Enterprises Limited, Goregaon, Mumbai, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajashri","family":"Parab","sequence":"additional","affiliation":[{"name":"Piramal Enterprises Limited, Goregaon, Mumbai, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zarine E.","family":"Patel","sequence":"additional","affiliation":[{"name":"Piramal Enterprises Limited, Goregaon, Mumbai, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandip","family":"Kuldharan","sequence":"additional","affiliation":[{"name":"Piramal Enterprises Limited, Goregaon, Mumbai, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vijayaphanikumar","family":"Yemparala","sequence":"additional","affiliation":[{"name":"Piramal Enterprises Limited, Goregaon, Mumbai, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prabhu Dutt","family":"Mishra","sequence":"additional","affiliation":[{"name":"Piramal Enterprises Limited, Goregaon, Mumbai, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prafull","family":"Ranadive","sequence":"additional","affiliation":[{"name":"Piramal Enterprises Limited, Goregaon, Mumbai, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisette","family":"D'Souza","sequence":"additional","affiliation":[{"name":"Bioorganic Chemistry Laboratory, CSIR-National Institute of Oceanography, Dona Paula, Goa, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koteppa","family":"Pari","sequence":"additional","affiliation":[{"name":"Piramal Enterprises Limited, Goregaon, Mumbai, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Sivaramkrishnan","sequence":"additional","affiliation":[{"name":"Piramal Enterprises Limited, Goregaon, Mumbai, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2005.01138.x"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.9.2188"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.1.275-280.2004"},{"key":"e_1_3_3_5_2","first-page":"1081","article-title":"The 10 X '20 initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020","volume":"15","author":"Infectious Diseases Society of America","year":"2010","unstructured":"Infectious Diseases Society of America. 2010. The 10 X '20 initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020. Clin. Infect. Dis. 15:1081\u20131083.","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1086\/595011"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1C437"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.44.2.655-656.2006"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2010.02.005"},{"key":"e_1_3_3_10_2","unstructured":"MahajanGBGeorgeSDRanadivePVMishraPDSEyyammadichiyilSSPanshikarRMSawantSNKrishnaSSivakumarMPariKPrabhaDD'SouzaLNaikCGPatelZESivakumarMThomasBVishwakarmaR. 2007. PM181104 and related antibacterial compounds production pharmaceutical compositions and therapeutic use. International Patent Cooperation Treaty Application WO\/2007\/119201 A3."},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.3390\/md11020387"},{"key":"e_1_3_3_12_2","unstructured":"Ca\u00f1edo Hern\u00e1ndezLMRomero Mill\u00e1nFFern\u00e1ndez MedardeAFern\u00e1ndez ChimenoRIHidalgo VillarJC. 2012. Peptides as bioactive compounds. International Patent Cooperation Treaty Application WO\/2012\/062906."},{"key":"e_1_3_3_13_2","volume-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically","author":"National Committee for Clinical Laboratory Standards","year":"2000","unstructured":"National Committee for Clinical Laboratory Standards. 2000. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A5, 5th ed. National Committee for Clinical Laboratory Standards, Wayne, PA.","edition":"5"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.11.3561-3566.2003"},{"key":"e_1_3_3_15_2","volume-title":"1st Global Forum on Bacterial Infections: Balancing Treatment Access and Antibiotic Resistance 2011","author":"Mahajan GB","year":"2011","unstructured":"MahajanGBShanbhagPSivaramakrishnanH. 2011. Mode of action of antibiotic PM181104 on bacteria, abstr registration no. 5SN3KNFPHL. 1st Global Forum on Bacterial Infections: Balancing Treatment Access and Antibiotic Resistance 2011. The Center for Disease Dynamics Economics & Policy, New Delhi, India."},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1021\/np800783b"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01059-13","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01059-13","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T22:31:55Z","timestamp":1645482715000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01059-13"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":15,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["10.1128\/AAC.01059-13"],"URL":"https:\/\/doi.org\/10.1128\/aac.01059-13","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11]]},"assertion":[{"value":"2013-05-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-08-07","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-10-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}